Antidepressant therapy with milnacipran and venlafaxine

References

• O’ConnorEAWhitlockEPBeilTLGaynesBNScreening for depression in adult patients in primary care settings: A systematic evidence reviewAnn Intern Med200915179380319949145
   PubMed Web of Science ®Google Scholar
• LépineJPGastparMMendlewiczJDepression in the community: The first pan-European study DEPRES (Depression Research in European Society)Int Clin Psychopharmacol199711929
   Web of Science ®Google Scholar
• StahlSMGradyMMMoretCBrileyMSNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressantsCNS Spectr20051073274716142213
   PubMed Web of Science ®Google Scholar
• KochSHemrick-LueckeSKThompsonLKComparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in ratsNeuropharmacology200345793594414573386
   PubMed Web of Science ®Google Scholar
• VaishnaviSNNemeroffCBPlottSJMilnacipran: A comparative analysis of human monoamine uptake and transporter binding affinityBiol Psychiatry200455332032214744476
   PubMed Web of Science ®Google Scholar
• PerettiSJudgeRHindmarchISafety and tolerability considerations: Tricyclic antidepressants vs selective serotonin reuptake inhibitorsActa Psychiatr Scand2000403Suppl1725
   Web of Science ®Google Scholar
• KasperSPletanYSollesATournouxAComparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial resultsInt Clin Psychopharmacol199611Suppl 435398923125
   PubMed Web of Science ®Google Scholar
• SteenADen BoerJAA double-blind six months comparative study of milnacipran and clomipramine in major depressive disorderInt Clin Psychopharmacol19971252692819466161
   PubMed Web of Science ®Google Scholar
• Lopez-IborJGuelfiJDPletanYMilnacipran and selective serotonin reuptake inhibitors in major depressionInt Clin Psychopharmacol199611Suppl 441468923126
   PubMed Web of Science ®Google Scholar
• MontgomerySABaldwinDSBlierPWhich antidepressants have demonstrated superior efficacy? A review of the evidenceInt Clin Psychopharmacol200722632332917917550
   PubMed Web of Science ®Google Scholar
• BauerMTharmanathanPVolzHPThe effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysisEur Arch Psychiatry Clin Neurosci2009259317218519165525
   PubMed Web of Science ®Google Scholar
• PapakostasGIThaseMEFavaMAre antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agentsBiol Psychiatry200762111217122717588546
   PubMed Web of Science ®Google Scholar
• DebonnelGSaint-AndréEHébertCDifferential physiological effects of a low dose and high doses of venlafaxine in major depressionInt J Neuropsychopharmacol2007101516116690006
   PubMed Web of Science ®Google Scholar
• GutierrezMAStimmelGLAisoJYVenlafaxine: A 2003 updateClin Ther20032582138215414512125
   PubMed Web of Science ®Google Scholar
• AnsseauMVon FrenckellRGérardMAInterest of a loading dose of milnacipran in endogenous depressive inpatients. Comparison with the standard regimen and with fluvoxamineEur Neuropsychopharmacol199111131211821700
   PubMedGoogle Scholar
• HayashiMMimuraMOtsuboTEffect of high-dose milnacipran in patients with depressionNeuropsychiatric Dis Treat200735699702
   Google Scholar
• OkumuraKFurukawaTARemission rates with milnacipran 100 mg/day and 150 mg/day in the long term treatment of major depressionClin Drug Invest2006263135142
   Web of Science ®Google Scholar
• OliéJ-PGourionDMontagneAMilnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: A 24-week randomized, double-blind exploratory studyNeuropsychiatr Dis Treat20106717920396639
   PubMed Web of Science ®Google Scholar
• MontgomerySAAsbergMA new depression scale designed to be sensitive to changeBr J Psychiatry197913382389444788
   PubMed Web of Science ®Google Scholar
• SpencerCMWildeMIMilnacipran. A review of its use in depressionDrugs19985634054279777315
   PubMed Web of Science ®Google Scholar
• DemyttenaereKHuygensRVan BuggenhoutRTamsulosin as an effective treatment for reboxetine-associated urinary hesitancyInt Clin Psychopharmacol200116635335511712624
   PubMed Web of Science ®Google Scholar
• KasperSWolfRSuccessful treatment of reboxetine-induced urinary hesitancy with tamsulosinEur Neuropsychopharmacol200212211912211872327
   PubMed Web of Science ®Google Scholar
• ScatesACDoraiswamyPMReboxetine: A selective norepinephrine reuptake inhibitor for the treatment of depressionAnn Pharmacother200034111302131211098346
   PubMed Web of Science ®Google Scholar
• BaldwinDMorenoRABrileyMResolution of sexual dysfunction during acute treatment of major depression with milnacipranHum Psychopharmacol200823652753218536065
   PubMed Web of Science ®Google Scholar
• TakahashiHIshigookaJImprovement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switching to milnacipranClin Neuropharmacol200932317717819483494
   PubMed Web of Science ®Google Scholar
• BaldwinDThomasSBirtwistleJEffects of antidepressant drugs on sexual functionInt J Psychiatry Clin Pract199714758
   PubMedGoogle Scholar
• ParisBLOgilvieBWScheinkoenigJAIn vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipranDrug Metab Dispos200937102045205419608694
   PubMed Web of Science ®Google Scholar
• ShamsMEArnethBHiemkeCCYP2D6 polymorphism and clinical effect of the antidepressant venlafaxineJ Clin Pharm Ther200631549350216958828
   PubMed Web of Science ®Google Scholar
• AlvánGBechtelPIseliusLGundert-RemyUHydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEur J Clin Pharmacol19903965335372151318
   PubMed Web of Science ®Google Scholar
• CuppMJTracyTSCytochrome P450: New nomenclature and clinical implicationsAm Fam Physician19985711071169447218
   PubMed Web of Science ®Google Scholar
• LauniainenTRasanenIVuoriEOjanperäIFatal venlafaxine poisonings are associated with a high prevalence of drug interactionsInt J Legal Med2010430 [Epub ahead of print]
   Web of Science ®Google Scholar
• MontgomerySATolerability of serotonin norepinephrine reuptake inhibitor antidepressantsCNS Spectr2008137 Suppl 11273318622372
   PubMed Web of Science ®Google Scholar
• FantonLBévalotFGraitHFatal intoxication with milnacipranJ Forensic Leg Med20081538839018586210
   PubMedGoogle Scholar
• TiihonenJLönnqvistJWahlbeckKAntidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohortArch Gen Psychiatry200663121358136717146010
   PubMed Web of Science ®Google Scholar
• CheetaSSchifanoFOyefesoAAntidepressant-related deaths antidepressant prescriptions in England and Wales, 1998–2000Br J Psychiatry2004184414714702226
   PubMed Web of Science ®Google Scholar
• HawtonKBergenHSimkinSToxicity of antidepressants: Rates of suicide relative to prescribing and non-fatal overdoseBr J Psychiatry201019635435820435959
   PubMed Web of Science ®Google Scholar